Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
115年05月僑外投資持股
Regulatory Filings Classification · 90% confidence The document is a statutory foreign and mainland China investor shareholding statistics table (“僑外及大陸地區投資人投資持股情形統計表”) filed on the Open Information Observatory of Taiwan. It is a periodic regulatory disclosure of aggregated shareholdings by foreign and mainland investors, not an earnings release, proxy, or an annual/interim report. It does not report a specific major investor crossing a threshold but is a general compliance form. This fits the fallback category of general regulatory announcements: Regulatory Filings (RNS).
2026-05-22 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document is a Q1 (“115年1季申報作業”) financial disclosure showing detailed actual financial data (investment amounts, share ratios, profit/loss) for overseas subsidiaries of the listed company 杏輝藥品工業. It is part of the company’s interim/quarterly reporting, not a simple announcement of publication or a full annual report. Therefore, it fits the Interim/Quarterly Report category. Q1 2026
2026-05-15 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 90% confidence The document is a regulatory disclosure on the public information platform (公開資訊觀測站) showing specific investment details into Mainland China for Q1 of year 115. It contains tables of remitted amounts, methods of investment, equity stakes, and related footnotes. It is not a full quarterly interim report (no P&L or B/S), not an earnings release or management presentation, nor a change-in-management, proxy, or dividend notice. It is a standalone regulatory compliance filing disclosing cross‐border investment details, which falls under the general Regulatory Filings category (RNS).
2026-05-15 Chinese
115年第1季財務報告書 — 202601_1734_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report for the first quarter (民國115及114年第1季) including full interim financial statements (balance sheet, income statement, cash flows, notes) and an auditor’s review report. It is substantive financial data for a period shorter than a full year (Q1), not merely an announcement or certification. Therefore it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 90% confidence The document originates from Taiwan’s public information platform (公開資訊觀測站) and presents the consolidated statement of changes in equity for the first quarter of the 115th fiscal year (民國115年第1季), with detailed balances and movements. It is substantive financial data for a quarter and is not merely an announcement or link to a report. Therefore, it qualifies as an Interim/Quarterly Report. Q1 2026
2026-05-15 Chinese
115年第1季資產負債表
Interim / Quarterly Report Classification · 87% confidence The document is a consolidated balance sheet (合併資產負債表) showing detailed financial line items and amounts for the first quarter of 民國115年 (Q1 2026) compared with prior period and year‐end. It contains actual financial statement data for a period shorter than a full fiscal year, which is characteristic of an Interim/Quarterly Report. Q1 2026
2026-05-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.